AVIR Atea Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1593899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-5.7%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.2%
ROA-57.2%
ROIC (approx.)-86.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $148.02M | $144.10M |
| SG&A expense | $32.86M | $48.85M |
| Operating income | -$180.89M | -$192.95M |
| Pretax income | -$164.51M | -$167.46M |
| Income tax | -$6.16M | $925,000 |
| Net income | -$158.35M | -$168.38M |
| EBITDA | -$180.47M | -$192.53M |
| EPS (basic) | -1.94 | -2.00 |
| EPS (diluted) | -1.94 | -2.00 |
| Weighted avg. shares (diluted) | 81.50M | 84.26M |
| Balance sheet | ||
| Cash & equivalents | $95.71M | $64.70M |
| Short-term investments | $206.12M | $390.02M |
| Current assets | $310.99M | $462.36M |
| PP&E, net | $457,000 | $873,000 |
| Total assets | $315.22M | $464.67M |
| Current liabilities | $39.78M | $18.60M |
| Total liabilities | $39.78M | $25.80M |
| Shareholders' equity | $275.43M | $438.87M |
| Shares outstanding | 78.13M | 84.46M |
| Cash flow statement | ||
| Operating cash flow | -$132.03M | -$135.50M |
| Investing cash flow | $188.79M | $56.10M |
| Financing cash flow | -$25.75M | $267,000 |
| Depreciation & amortization | $416,000 | $416,000 |
| Stock-based compensation | $20.72M | $51.77M |
| Share buybacks | $25.52M | $0 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.